Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XENE | US
-0.11
-0.27%
Healthcare
Biotechnology
30/06/2024
04/10/2024
40.73
39.81
41.38
39.81
Xenon Pharmaceuticals Inc. a clinical-stage biopharmaceutical company engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496 a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101 a Kv7 potassium channel opener which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352 a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy and other indications including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby Canada.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
26.4%1 month
28.4%3 months
33.5%6 months
33.1%-
-
3.47
0.01
0.01
-11.81
10.87K
-0.06
-233.68M
3.09B
3.09B
-
-
-
-100.00
-26.71
11.41
4.78
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.72
Range1M
4.06
Range3M
8.77
Rel. volume
0.58
Price X volume
7.25M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | APLS | Biotechnology | 27.51 | 3.35B | -3.41% | n/a | 179.52% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 10.46 | 3.17B | 7.17% | n/a | 10.63% |
Amicus Therapeutics Inc | FOLD | Biotechnology | 10.6 | 3.14B | 0.09% | n/a | 335.08% |
Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 49.63 | 3.03B | -2.71% | n/a | 642.15% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.81 | 0.76 | Cheaper |
Ent. to Revenue | 10,874.60 | 3,674.48 | Expensive |
PE Ratio | - | 38.01 | - |
Price to Book | 3.47 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 33.49 | 74.67 | Lower Risk |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 3.09B | 3.73B | Par |